SARS-CoV-2 Bamlanivimab resistance sequencing

As part of the ACTIV-2/A5401 randomized clinical trial (NCT04518410), non-hospitalized participants with symptomatic SARS-CoV-2 infection were given bamlanivimab (700mg or 7000mg) or placebo treatment. We performed targeted Spike (S) gene next-generation sequencing to detect bamlanivimab resistance mutations. Using this data, we can assess whether in vivo emergence of SARS-CoV-2 resistance mutations alters viral replication dynamics or therapeutic efficacy in the immune-competent population.